藥捷安康(02617.HK)新藥替恩戈替尼獲FDA快速通道認證
藥捷安康(02617.HK)宣布,其自主研發的多靶點激(酉每)抑制劑「替恩戈替尼」(TT-00420),已獲美國食品藥物管理局(FDA)授予治療轉移性去勢抵抗性前列腺癌的快速通道認證。
公司表示,替恩戈替尼目前處於全球三期註冊實驗的多靶點激(酉每)抑制劑,靶向FGFR/VEGFR、JAK和Aurora激(酉每)發揮抗腫瘤作用,目前正在美國與中國進行的臨床試驗顯示,其在多種實體瘤治療中具有療效潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.